A review of phase III clinical trials of US FDA-approved biologic therapies for chronic rhinosinusitis with nasal polyposis Review

publication date

  • June 1, 2022

webpage

published in

keywords

  • biologics
  • chronic rhinosinusitis
  • dupilumab
  • mepolizumab
  • nasal polyposis
  • omalizumab

start page

  • 655

end page

  • 662

volume

  • 14

issue

  • 8